Free Trial

Inventiva (NASDAQ:IVA) Shares Gap Up - What's Next?

Inventiva logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Inventiva shares opened higher, rising from a prior close of $3.68 to $3.81, but later traded at $3.595; the article also reports the stock was down 6.7%.
  • Analysts give the stock a “Moderate Buy” consensus with an average price target of $14.67; ratings include one Strong Buy, seven Buys, and one Sell.
  • Inventiva’s lead candidate, lanifibranor, is in a Phase 3 trial for MASH, with topline results expected in Q4 2026; the company says positive results could lead to U.S. regulatory filing and a potential 2028 launch.
  • MarketBeat previews the top five stocks to own by December 1st.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report)'s share price gapped up before the market opened on Monday. The stock had previously closed at $3.68, but opened at $3.81. Inventiva shares last traded at $3.5950, with a volume of 236,477 shares traded.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Wall Street Zen upgraded Inventiva from a "sell" rating to a "hold" rating in a report on Saturday, October 3rd. Guggenheim boosted their price objective on shares of Inventiva from $11.00 to $14.00 and gave the stock a "buy" rating in a research note on Tuesday, September 15th. Truist Financial upped their price objective on shares of Inventiva from $13.00 to $18.00 and gave the stock a "buy" rating in a report on Friday, October 2nd. Weiss Ratings lowered shares of Inventiva from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday. Finally, Piper Sandler reiterated an "overweight" rating on shares of Inventiva in a research note on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $14.67.

Get Our Latest Stock Report on Inventiva

Inventiva Stock Down 6.7%

The company has a 50-day simple moving average of $3.64 and a 200 day simple moving average of $4.76.

Inventiva (NASDAQ:IVA - Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The firm had revenue of $0.75 million for the quarter. On average, equities analysts anticipate that Inventiva S.A. Sponsored ADR will post -0.75 earnings per share for the current year.

Institutional Trading of Inventiva

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Commonwealth Equity Services LLC raised its stake in shares of Inventiva by 7.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 89,853 shares of the company's stock valued at $332,000 after buying an additional 5,857 shares in the last quarter. Platt Investment Counsel LLC acquired a new stake in shares of Inventiva during the 3rd quarter valued at about $45,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Inventiva by 78.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,600 shares of the company's stock valued at $142,000 after acquiring an additional 17,000 shares in the last quarter. Engineers Gate Manager LP boosted its position in shares of Inventiva by 155.5% during the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock valued at $269,000 after acquiring an additional 43,280 shares in the last quarter. Finally, Seven Fleet Capital Management LP bought a new stake in Inventiva in the first quarter valued at about $1,111,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Company Profile

(Get Free Report)

Inventiva S.A. is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders. Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial. The company expects topline trial results in Q4 2026 and, if results are positive, plans to pursue U.S. regulatory approval, with a potential commercial launch in 2028.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Inventiva Right Now?

Before you consider Inventiva, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.

While Inventiva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines